Taysha Gene Therapies (NASDAQ:TSHA) Announces Quarterly Earnings Results

Taysha Gene Therapies (NASDAQ:TSHAGet Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01, Zacks reports. The company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $3.70 million. During the same period last year, the company earned ($0.28) EPS.

Taysha Gene Therapies Trading Up 17.5 %

Shares of Taysha Gene Therapies stock traded up $0.45 during trading on Wednesday, hitting $3.02. The stock had a trading volume of 2,403,111 shares, compared to its average volume of 2,423,621. Taysha Gene Therapies has a 12 month low of $0.50 and a 12 month high of $3.89. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. The firm’s fifty day simple moving average is $2.61 and its 200-day simple moving average is $2.11. The stock has a market cap of $564.79 million, a PE ratio of -4.48 and a beta of 0.37.

Analysts Set New Price Targets

A number of research firms recently commented on TSHA. Piper Sandler assumed coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price target for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Jefferies Financial Group reissued a “buy” rating and issued a $8.00 target price (up from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies has an average rating of “Buy” and an average price target of $7.00.

Get Our Latest Stock Analysis on Taysha Gene Therapies

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Stories

Earnings History for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.